These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 24735237)
1. Cost-effectiveness of family history-based colorectal cancer screening in Australia. Ouakrim DA; Boussioutas A; Lockett T; Hopper JL; Jenkins MA BMC Cancer; 2014 Apr; 14():261. PubMed ID: 24735237 [TBL] [Abstract][Full Text] [Related]
2. Improving Australian National Bowel Cancer Screening Program outcomes through increased participation and cost-effective investment. Worthington J; Lew JB; Feletto E; Holden CA; Worthley DL; Miller C; Canfell K PLoS One; 2020; 15(2):e0227899. PubMed ID: 32012174 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Screening Colonoscopy in Iranian High Risk Population. Javadinasab H; Daroudi R; Salimzadeh H; Delavari A; Vezvaie P; Malekzadeh R Arch Iran Med; 2017 Sep; 20(9):564-571. PubMed ID: 29048918 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of the benefits, harms and cost-effectiveness of potential alternatives to iFOBT testing for colorectal cancer screening in Australia. Lew JB; St John DJB; Macrae FA; Emery JD; Ee HC; Jenkins MA; He E; Grogan P; Caruana M; Sarfati D; Greuter MJE; Coupé VMH; Canfell K Int J Cancer; 2018 Jul; 143(2):269-282. PubMed ID: 29441568 [TBL] [Abstract][Full Text] [Related]
5. Long-term benefits and harms of early colorectal cancer screening in German individuals with familial cancer risk. Sroczynski G; Hallsson LR; Mühlberger N; Jahn B; Rehms R; Hoffmann S; Crispin A; Lindoerfer D; Mansmann U; Siebert U Int J Cancer; 2024 Feb; 154(3):516-529. PubMed ID: 37795630 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of screening for colorectal cancer in the general population. Frazier AL; Colditz GA; Fuchs CS; Kuntz KM JAMA; 2000 Oct; 284(15):1954-61. PubMed ID: 11035892 [TBL] [Abstract][Full Text] [Related]
7. Benefits, harms and cost-effectiveness of cancer screening in Australia: an overview of modelling estimates. Lew JB; Feletto E; Wade S; Caruana M; Kang YJ; Nickson C; Simms KT; Procopio P; Taylor N; Worthington J; Smith D; Canfell K Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384886 [TBL] [Abstract][Full Text] [Related]
8. Family history-based colorectal cancer screening in Australia: A modelling study of the costs, benefits, and harms of different participation scenarios. Dillon M; Flander L; Buchanan DD; Macrae FA; Emery JD; Winship IM; Boussioutas A; Giles GG; Hopper JL; Jenkins MA; Ait Ouakrim D PLoS Med; 2018 Aug; 15(8):e1002630. PubMed ID: 30114221 [TBL] [Abstract][Full Text] [Related]
9. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330 [TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand. Phisalprapa P; Supakankunti S; Chaiyakunapruk N J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247 [No Abstract] [Full Text] [Related]
11. Comparative effectiveness and cost-effectiveness analysis of a urine metabolomics test vs. alternative colorectal cancer screening strategies. Barichello S; Deng L; Ismond KP; Loomes DE; Kirwin EM; Wang H; Chang D; Svenson LW; Thanh NX Int J Colorectal Dis; 2019 Nov; 34(11):1953-1962. PubMed ID: 31673772 [TBL] [Abstract][Full Text] [Related]
12. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514 [TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness and National Effects of Initiating Colorectal Cancer Screening for Average-Risk Persons at Age 45 Years Instead of 50 Years. Ladabaum U; Mannalithara A; Meester RGS; Gupta S; Schoen RE Gastroenterology; 2019 Jul; 157(1):137-148. PubMed ID: 30930021 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of colorectal cancer screening programmes using sigmoidoscopy and immunochemical faecal occult blood test. Senore C; Hassan C; Regge D; Pagano E; Iussich G; Correale L; Segnan N J Med Screen; 2019 Jun; 26(2):76-83. PubMed ID: 30180780 [TBL] [Abstract][Full Text] [Related]
15. Contrasting Effectiveness and Cost-Effectiveness of Colorectal Cancer Screening Under Commercial Insurance vs. Medicare. Ladabaum U; Mannalithara A; Brill JV; Levin Z; Bundorf KM Am J Gastroenterol; 2018 Dec; 113(12):1836-1847. PubMed ID: 29904156 [TBL] [Abstract][Full Text] [Related]
16. Long-term evaluation of benefits, harms, and cost-effectiveness of the National Bowel Cancer Screening Program in Australia: a modelling study. Lew JB; St John DJB; Xu XM; Greuter MJE; Caruana M; Cenin DR; He E; Saville M; Grogan P; Coupé VMH; Canfell K Lancet Public Health; 2017 Jul; 2(7):e331-e340. PubMed ID: 29253458 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness simulation and analysis of colorectal cancer screening in Hong Kong Chinese population: comparison amongst colonoscopy, guaiac and immunologic fecal occult blood testing. Wong CK; Lam CL; Wan YF; Fong DY BMC Cancer; 2015 Oct; 15():705. PubMed ID: 26471036 [TBL] [Abstract][Full Text] [Related]
18. Would initiating colorectal cancer screening from age of 45 be cost-effective in Germany? An individual-level simulation analysis. Lwin MW; Cheng CY; Calderazzo S; Schramm C; Schlander M Front Public Health; 2024; 12():1307427. PubMed ID: 38454984 [TBL] [Abstract][Full Text] [Related]
19. Comparative effectiveness of screening strategies for colorectal cancer. Barzi A; Lenz HJ; Quinn DI; Sadeghi S Cancer; 2017 May; 123(9):1516-1527. PubMed ID: 28117881 [TBL] [Abstract][Full Text] [Related]
20. The National Bowel Cancer Screening Program: time to achieve its potential to save lives. Ee H; St John J Public Health Res Pract; 2019 Jul; 29(2):. PubMed ID: 31384889 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]